Trials / Completed
CompletedNCT00891735
A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR)
A Phase III, Double-masked, Multicenter, Randomized, Active Treatment-controlled Study of the Efficacy and Safety of 0.5 mg and 2.0 mg Ranibizumab Administered Monthly or on an As-needed Basis (PRN) in Patients With Subfoveal Neovascular Age-related Macular Degeneration
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,097 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase III, multicenter, randomized, double-masked, dose-comparison study of the efficacy and safety of ranibizumab injection administered intravitreally to patients with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). Results are presented for the first 12 months of the study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ranibizumab | Sterile solution for intravitreal injection. |
Timeline
- Start date
- 2009-07-01
- Primary completion
- 2011-08-01
- Completion
- 2012-08-01
- First posted
- 2009-05-01
- Last updated
- 2013-01-18
- Results posted
- 2013-01-18
Locations
99 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00891735. Inclusion in this directory is not an endorsement.